Exploiting this strategy, we performed phosphoproteomic profiling using a combined immunoaffinity/LC-MS/MS approach across multiple MSCV-Neu (HER2), Tp53-null (p53) and PyMT tumours, as illustrated in Figure 1A. The lineage of each tumour from its original clone is outlined in Additional file 1: Figure S1A. This evidence concerns the gene TP53 and neoplasm.